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An acute but transient response to insulin is essential for glucose homeostasis in mammals. Chak-
raborty et al. (2010) uncover a new feedback mechanism regulating insulin signaling. They show
that the inositol pyrophosphate IP7, which is produced in response to insulin, inhibits the Akt
kinase, a primary effector of insulin signaling.Pancreatic b cells produce insulin in
response to the rise in circulating glucose
levels after a meal. Insulin restores basal
blood glucose levels by eliciting distinct
metabolic responses in target tissues,
including the stimulation of glucose
uptake into skeletal muscle and adipose
tissue and the inhibition of glucose output
in the liver. The homeostatic response to
insulin must occur rapidly but transiently
following a spike in blood glucose. Thus,
proper control over both stimulatory
and inhibitory signals affecting the re-
sponse to insulin is important for prevent-
ing metabolic imbalance and common
metabolic diseases such as type-2 dia-
betes. Chakraborty et al. (2010) now
identify a new feedback mechanism that
attenuates insulin signaling. They show
that the production of a specific inositol
pyrophosphate, which is stimulated
by insulin, inhibits canonical insulin sig-
naling by preventing activation of the
kinase Akt.
Whereas the response to insulin varies
among tissues, the signal transduction
pathway triggered by insulin is conserved
(Taniguchi et al., 2006; Figure 1A). Insulin
binds to and activates cell surface
insulin receptors, and these receptor tyro-
sine kinases phosphorylate the insulin
receptor substrate (IRS) proteins on
specific tyrosine residues. Phosphory-
lated IRS proteins serve as scaffolding
adaptors for signaling proteins, the most
important of which is the class IA phos-
phatidylinositol 3-kinase (PI3K). Engage-
ment of PI3K by the IRS protein activates
this lipid kinase at the plasma membrane,
where its substrate phosphatidylinositol-
4,5-bisphosphate (PIP2) is abundant,stimulating the production of the key lipid
second messenger phosphatidylinositol-
3,4,5-trisphosphate (PIP3). PIP3 then
binds the pleckstrin homology (PH)
domain of the serine/threonine kinase Akt,
allowing two other kinases—the phos-
phoinositide-dependent kinase (PDK1)
and the mammalian target of rapamycin
(mTOR) complex 2 (mTORC2) —to phos-
phorylate and activate Akt. Akt is a major
effector of the insulin response, and its
downstream substrates directly mediate
many of the metabolic effects of insulin
(Manning and Cantley, 2007). Insulin
resistance is a hallmark of type-2 diabetes
and is characterized by an inability of
insulin to signal to Akt (Whiteman et al.,
2002).
Insulin signaling can be inhibited at
multiple steps between the insulin
receptor and Akt activation. The best-
characterized inhibitors include lipid
phosphatases such as PTEN and SHIP2,
which dephosphorylate lipids produced
by PI3K. In addition, insulin induces
signaling pathways that can promote
inhibitory phosphorylation of the IRS
proteins, preventing the activation of
PI3K and Akt. For instance, Akt signaling
activates mTOR complex 1 (mTORC1)
and its downstream target S6K1, and
these ser/thr kinases can directly phos-
phorylate serine residues on IRS1, leading
to its inhibition (Harrington et al., 2005). In
this manner, the stimulation of mTORC1
activity in response to insulin creates an
inhibitory feedback mechanism that
decreases insulin signaling. Chakraborty
et al. now report that production of a
specific inositol pyrophosphate repre-
sents another mechanism by which anCell 143, Dinsulin-stimulated pathway leads to atten-
uation of insulin signaling.
Inositol phosphates are a diverse group
of signaling molecules in which hydroxyl
groups positioned around an inositol ring
are phosphorylated in different combina-
tions by an array of inositol phosphate
kinases. One such kinase, inositol hexa-
kisphosphate (IP6) kinase 1 (IP6K1), pro-
duces a pyrophosphate group at the 5
position of IP6 to generate 5-diphospho-
inositolpentakisphosphate (5-PP-IP5, or
IP7; Figure 1B). Studies on IP6K demon-
strate a role for the IP7 product in
promoting insulin production by pancre-
atic b cells (Illies et al., 2007). Of interest,
despite low blood insulin levels in the
Ip6k1 knockout mice due to defects in
insulin secretion, the levels of blood
glucose in these mice are normal, sug-
gesting that these mice have enhanced
peripheral insulin sensitivity (Bhandari
et al., 2008).
Chakraborty et al. examine the molec-
ular mechanism and physiological conse-
quences of the increased responsiveness
to insulin suggested by the IP6K1
knockout mouse phenotype. Using insulin
and insulin-like growth factor 1 (IGF-1) to
stimulate hepatocytes and mouse
embryo fibroblasts, the authors demon-
strate enhanced Akt activation in Ip6k1
knockout cells relative to wild-type. Of
interest, the authors also find that insulin
and IGF-1 stimulate a gradual increase
in the levels of the IP6K1 product IP7 in
wild-type cells, and this inositol pyro-
phosphate inhibits Akt translocation to
the plasmamembrane and its subsequent
phosphorylation by PDK1. Taken together
with a previous study by this groupecember 10, 2010 ª2010 Elsevier Inc. 861
Figure 1. The Insulin Signaling Pathway and Inositol Phosphates
(A) The figure shows the canonical insulin signaling pathway leading to
activation of the serine/threonine kinase Akt. Chakraborty et al. (2010) show
that insulin also stimulates the inositol phosphate kinase IP6K1 to produce
IP7 (5-diphosphoinositolpentakisphosphate), which in turn inhibits Akt.
The authors’ results suggest a model for the inhibition of Akt by IP7. In this
model, IP7 binding to the PH domain of Akt prevents the translocation of Akt
to the membrane by preventing the binding of PIP3 (phosphatidylinositol-
3,4,5-trisphosphate) to the same domain, thus blocking insulin signaling
to Akt.
(B) Inositol derivatives serve as signaling molecules when phosphorylated on
distinct hydroxyl groups on the inositol ring. The figure shows the reactions
catalyzed by phosphatidylinositol 3-kinase (PI3K) and IP6K1. PI3K phosphor-
ylates the 3 position of PIP2 (phosphatidylinositol-4,5-bisphosphate) to make
PIP3. IP6K1 phosphorylates the phosphate group at the 5 position of IP6
(inositol hexakisphosphate) to generate IP7.demonstrating that IP7 can
bind directly to the PH
domain of Akt (Luo et al.,
2003), the data suggest that
IP7 competes with PIP3 for
binding to Akt, thereby block-
ing Akt activation (Figure 1A).
Thus, insulin and IGF-1 stimu-
late the production of two
phosphoinositol species,
PIP3 through PI3K and IP7
through IP6K1 (Figure 1B),
which have reciprocal effects
on Akt activation.
These cell-intrinsic effects
of IP6K1 and its product IP7
suggest a mechanistic basis
for the enhanced insulin sen-
sitivity implied from previous
studies on the Ip6k1 knock-
out mice (Bhandari et al.,
2008). Measuring systemic
responses to insulin, Chakra-
borty et al. (2010) find that
Ip6k1 knockout mice display
enhanced activation of Akt in
response to insulin in both
skeletal muscle and adipose
tissue, accompanied by in-
creased glucose uptake into
these tissues. Importantly,
the Ip6k1 knockout mice are
lean and resistant to both
age- and diet-induced obe-
sity, showing greatly dimin-
ished white adipose depots.
As it is well known that
increased adiposity is closely
associated with the develop-ment of systemic insulin resistance
(Guilherme et al., 2008), the lean pheno-
type of the Ip6k1 knockout mice
confounds the interpretation of their
enhanced insulin sensitivity. Indeed, the
improved insulin sensitivity of the
knockout mice is more pronounced on
a high fat-diet, on which the control mice
develop obesity and insulin resistance.
Therefore, the beneficial effects of
IP6K1 loss on global insulin action reflect
both increased cellular insulin signaling
and the systemic effects of decreased
adiposity. The lean nature of the Ip6k1
knockout mice appears to be due to
an increase in lean muscle mass and
in the breakdown of fatty acids by
b oxidation. However, the authors also
demonstrate that Ip6k1 plays an impor-862 Cell 143, December 10, 2010 ª2010 Elsetant role in promoting adipocyte differen-
tiation.
This study raises some interesting
questions regarding control of the insulin
response at both the cellular and organ-
ismal levels. The findings by Chakraborty
et al. that the same signals that increase
the levels of PIP3 also increase the levels
of IP7, which appears to compete with
PIP3 for binding the Akt-PH domain,
suggest a rheostat-like control over Akt
activation. Although these inositol deriva-
tives bind with different affinities to the
Akt-PH domain, this model suggests
that the relative localized concentrations
of PIP3 and IP7 directly influence the
spatial and temporal status of Akt activa-
tion. Further studies are needed to deter-
mine how the ratios of PIP3 to IP7 changevier Inc.in metabolic tissues following
feeding and whether the rela-
tive levels of these opposing
molecules change under
different conditions of insulin
resistance. It will also be
important to understand the
mechanism by which insulin
and IGF-1, and perhaps other
growth factors, stimulate the
production of IP7 by IP6K1.
It remains possible that this
stimulation is downstream of
Akt, making this a classic
negative-feedback mecha-
nism analogous to that medi-
ated by mTORC1 and S6K1
(Harrington et al., 2005). Of
interest, the major metabolic
features of the Ip6k1 knock-
out phenotype—defects in
b cell insulin production,
resistance to obesity, and
improved peripheral insulin
sensitivity—are the same as
those reported for the S6k1
knockout mice (Um et al.,
2004), perhaps suggesting
a mechanistic link between
the IP6K and mTORC1 path-
ways. Finally, IP6K1 could
represent a new therapeutic
target to improve insulin
sensitivity in type-2 diabetics.
However, a major consider-
ation in the development of
such inhibitors is the involve-
ment of IP6K1 in pancreatic
insulin output (Illies et al.,2007; Bhandari et al., 2008). Though it is
clear that there are many new avenues
to explore, the findings reported by Chak-
raborty et al. add another key element
to the complex regulation of the insulin
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As mRNAs are generated, they are clothed with proteins to form messenger ribonucleoprotein
particles (mRNPs), which are then actively remodeled during various steps of gene expression.
Franks et al. (2010) now show that mRNP remodeling is required even for the death of an mRNA.Although we tend to sketch mRNAs as
naked molecules, they are rapidly assem-
bled into messenger ribonucleoprotein
particles (mRNPs) during transcription.
Proteins and protein complexes such as
the cap-binding complex, exon junction
complex, and nuclear poly(A)-binding
protein are specifically deposited on the
nascent transcript (Figure 1). Each of
these factors has the capacity to influence
downstream events such as mRNA
export and translation, and failure to
assemble an appropriate mRNP may
result in its decay through nuclear surveil-
lance pathways. Despite the ordered and
precise assembly of nuclear mRNPs,
these complexes are rather transient, as
by the time the transcript is being actively
translated in the cytoplasm, it has a very
different array of proteins associated
with it. The nuclear cap-binding complex
has been replaced by the translation
initiation factor eIF4E and its associated
proteins, the poly(A) tail is now bound
exclusively to the cytoplasmic poly(A)-
binding protein, and, at least for normal
mRNAs, exon junction complexes have
dissociated and returned to the nucleus.
Moreover, as an mRNA comes to theend of its useful life, the mRNP must be
completely disassembled to allow recy-
cling of its components. Several recent
studies have suggested that many of
these dramatic changes in the mRNP
can be modulated through posttransla-
tional modification and RNA chaperone
activity. However, the mechanism by
which mRNPs are finally undressed to
allow degradation of the mRNA has until
now remained a mystery.
In this issue, Franks et al. (2010)
uncover a role for the ATPase activity of
the nonsense-mediated decay (NMD)
factor hUPF1 in remodeling the mRNP to
allow 50-30 exonucleolytic decay of an
mRNA fragment. NMD is a well-charac-
terized mechanism that recognizes
mRNAs bearing premature termination
codons and can trigger an endonucleo-
lytic cleavage close to the site of prema-
ture translation termination. For this and
many other decay events, it had been
assumed that the 50-30 exonuclease
XRN1 and 30-50 exosome activity simply
displace any associated proteins as they
plough through the transcript. The work
from the Lykke-Andersen lab suggests
that exonucleolytic decay, at least the50-30 pathway, is not as robust as once
presumed. In fact, they show that XRN1
requires that UPF1 hydrolyze ATP in order
to dissociate other RNA binding factors
before it can act on the 30 fragment.
When UPF1 ATPase activity is impaired,
XRN1 fails to efficiently degrade the
mRNA and the fragment accumulates
along with its associated proteins, which
are then no longer available to bind other
transcripts. The authors further show
that granular structures known as pro-
cessing bodies (P bodies) may be the
location where improperly dressed
mRNPs are held. In addition, undegraded
RNA fragments could become substrates
for the rather mysterious process of cyto-
plasmic recapping (Otsuka et al., 2009) in
which the 50 monophosphate of the RNA
fragment is replaced with a methylated
cap structure. This may allow translation
of novel downstream open reading
frames or may result in sequestration of
translation initiation factors that could
dramatically impact the expression of
many other genes.
Although the hUPF1 protein has been
known to be essential for NMD for a long
time, the precise role of its ATPase activityecember 10, 2010 ª2010 Elsevier Inc. 863
